CeriBell, Inc. (NASDAQ:CBLL) Short Interest Down 18.6% in April

CeriBell, Inc. (NASDAQ:CBLL) saw a large drop in short interest in April. As of April 15th, there was short interest totaling 1,530,162 shares, a drop of 18.6% from the March 31st total of 1,880,159 shares. Based on an average daily volume of 249,548 shares, the short-interest ratio is currently 6.1 days. Approximately 5.1% of the company’s stock are short sold.

CeriBell Stock Performance

NASDAQ CBLL traded up $0.34 during trading on Friday, hitting $20.50. The company’s stock had a trading volume of 171,871 shares, compared to its average volume of 310,133. The company has a quick ratio of 9.35, a current ratio of 9.73 and a debt-to-equity ratio of 0.13. The firm has a 50 day moving average price of $19.15 and a 200 day moving average price of $18.46. The firm has a market cap of $776.34 million, a P/E ratio of -13.95 and a beta of 0.94. CeriBell has a 52 week low of $10.85 and a 52 week high of $24.33.

CeriBell (NASDAQ:CBLL) last issued its quarterly earnings results on Tuesday, February 24th. The company reported ($0.36) EPS for the quarter, topping the consensus estimate of ($0.43) by $0.07. CeriBell had a negative return on equity of 31.77% and a negative net margin of 59.97%.The company had revenue of $24.78 million for the quarter, compared to the consensus estimate of $23.95 million. Equities research analysts forecast that CeriBell will post -1.44 earnings per share for the current fiscal year.

Insider Transactions at CeriBell

In other news, CEO Xingjuan Chao sold 39,000 shares of the firm’s stock in a transaction dated Monday, April 6th. The stock was sold at an average price of $18.40, for a total transaction of $717,600.00. Following the completion of the sale, the chief executive officer directly owned 850,347 shares of the company’s stock, valued at $15,646,384.80. This trade represents a 4.39% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Josef Parvizi sold 16,714 shares of the stock in a transaction dated Thursday, February 19th. The shares were sold at an average price of $20.27, for a total value of $338,792.78. Following the transaction, the director directly owned 722,652 shares in the company, valued at approximately $14,648,156.04. This represents a 2.26% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 130,571 shares of company stock valued at $2,411,026 over the last 90 days. Company insiders own 20.10% of the company’s stock.

Institutional Inflows and Outflows

Several hedge funds have recently bought and sold shares of CBLL. Y Intercept Hong Kong Ltd acquired a new position in CeriBell in the first quarter worth $341,000. Strs Ohio acquired a new position in CeriBell in the first quarter worth $27,000. Caitong International Asset Management Co. Ltd boosted its stake in CeriBell by 8,735.5% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 2,739 shares of the company’s stock worth $60,000 after purchasing an additional 2,708 shares in the last quarter. Invesco Ltd. boosted its stake in CeriBell by 15.5% in the fourth quarter. Invesco Ltd. now owns 12,037 shares of the company’s stock worth $264,000 after purchasing an additional 1,618 shares in the last quarter. Finally, Creek Drive Management Group LLC acquired a new position in CeriBell in the fourth quarter worth $4,253,000.

Analysts Set New Price Targets

Several research firms recently issued reports on CBLL. BTIG Research reaffirmed a “buy” rating and set a $30.00 price objective on shares of CeriBell in a report on Wednesday, January 28th. Weiss Ratings reiterated a “sell (d-)” rating on shares of CeriBell in a report on Monday, April 6th. One research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, CeriBell presently has an average rating of “Moderate Buy” and an average price target of $23.20.

CeriBell Company Profile

CeriBell Corp (NASDAQ: CBLL) is a healthcare technology company specializing in the design, manufacture and sale of automated newborn hearing screening devices. The company offers a suite of medical diagnostic tools based on otoacoustic emissions (OAE) and auditory brainstem response (ABR) technologies, enabling early detection of auditory impairments in infants. CeriBell’s solutions are used in hospitals, birthing centers and audiology clinics to support universal newborn hearing screening programs aimed at improving language development outcomes through prompt intervention.

The company’s product portfolio includes handheld and desktop screening units, proprietary software for data management, and accessories designed to streamline testing workflows.